Significant Advance in Treatment of Breast Cancer Reported

In what may be a significant advance for the treatment of breast cancer, researchers at Montefiore Medical Center and the Moffitt Cancer Center and Research Institute have discovered they can more effectively wipe out diseased tissue when standard chemotherapy is combined with a drug that shuts down certain molecular pathways involved in causing cancer.

In a multicenter clinical trial reported in the Jully, 2006 issue of the Journal of Clinical Oncology, women with locally advanced breast cancer were given an oral medication that inhibits an enzyme called farnesyltransferase, in addition to routine chemotherapy, before undergoing surgery. Farnesyltransferase is required to set in motion a series of molecular events involved in the development of cancer.

Analysis of the breast tissue taken at surgery showed no signs of cancer in a third of the patients.

"The findings are extremely encouraging,” said Dr. Joseph Sparano, lead author of the study and director of the Breast Evaluation Center at the Montefiore-Einstein Cancer Center. “Eradication of cancer cells in breast tissue is a short-term endpoint that translates into a greater chance of cure in the long term. This combination of therapies definitely looks promising, and we are moving ahead with larger trials to confirm our results.”

The study included 21 women with locally advanced breast cancer who were considered suboptimal candidates for surgery because of the advanced stage of their disease. They received standard chemotherapy, doxorubicin and cyclophosphamide, given intravenously once every two weeks for four treatments. After each chemotherapy treatment, they also received 200 mg of tipifarnib, which inhibits farnesyltransferase, twice a day for six days. All patients then underwent a mastectomy or a lumpectomy.

Pathological analyses of breast tissue retrieved from the surgeries showed no cancerous tissue in seven patients, or 33 percent of the women who received the treatment, compared with 5 to 10 percent expected with chemotherapy alone.
The researchers also demonstrated that tipifarnib inhibited farnesyltransferase in tumor tissue by an average of 90 percent. Farnesyltransferase is essential for activating proteins, such as one called Ras, that contribute to the growth of cancer cells.

“This important study suggests that the proliferation and survival of breast tumor cells from one third of the patients in our study depended on proteins that were activated by farnesyltransferase,” said Dr. Said Sebti, coauthor of the study and associate director of the Moffitt Research Institute in Tampa, Florida.
“We believe that by switching off the farnesylation-dependent pathways we made the chemotherapy much more effective” said Dr. Sparano. “Our next step will be to combine tipifarnib with other types of standard chemotherapy in order to push the response rate even higher, and perform randomized trials that provide more definitive proof of the benefits of this treatment.”

The trial was performed by the New York Cancer Consortium, a multicenter clinical trials group funded by the National Cancer Institute to evaluate the newest and most promising cancer treatments. Montefiore Medical Center is the lead institution for this group. Each year, approximately 200 patients are enrolled in clinical trials conducted by the Consortium. The work was also partially funded by a grant from the National Cancer Institute to Dr. Septi.

Montefiore Medical Center, The University Hospital and Academic Medical Center for the Albert Einstein College of Medicine, ranks among the top one percent of all US hospitals based on its investments in medical innovation and cutting-edge technology.

Montefiore invests more in order to enable compassionate, personalized care and the most positive outcomes for patients and their families in New York, the tri-state area and beyond.

Montefiore’s unique combination of ‘state-of-the-art’ technology with ‘state-of-the-heart’ medical and nursing care in a teaching and research environment offer patients access to world-class medical experts, the newest and most innovative treatments and the best medical center experience anywhere.

This 1,062 bed medical center includes the Henry and Lucy Moses Division, the Jack D. Weiler Hospital and The Children’s Hospital at Montefiore, a large home healthcare agency and a 21-site medical group practice located throughout the Bronx and nearby Westchester.

Montefiore treats all major illnesses and has distinguished centers of excellence in cardiology and cardiac surgery, cancer care, tissue and organ transplantation, children’s health, women’s health, surgery and the surgical subspecialties. Montefiore Medical Center focuses on providing family-centered healthcare in a nurturing environment that extends well beyond its hospital and ambulatory settings.

www.montefiore.org

RELATED STORIES:
Fear a Mammogram? Follow These Tips   Breast cancer deaths decline more slowly for some   HER-2 Status Predicts Success of Chemotherapy in Breast Cancer Treatment   Scientists Break Genetic Code for Estrogen-Positive Breast Cancer   Breast-feeding debate heats up in Massachusetts   Intake of Vitamin D, Calcium Associated With Lower Risk of Breast Cancer Before Menopause   Adjuvant hormonal therapy reduces contralateral breast cancer risk   Estrogen-like chemical ups cancer risk in mice   Jefferson researchers uncover new evidence of prolactin’s possible role in breast cancer   Are breast cancer patients being kept in the dark?   Larger breasts confer higher breast cancer risk   Ospemifine may also help to prevent breast cancer   Concerns raised about surgeons performing occasional breast cancer operations   Breastfeeding reduces risk of breast cancer in women with a family history of the disease   MRI Changes Breast Cancer Treatment Choice; Increases Time to Treatment   Antidepressant doesn’t raise breast cancer risk   Hair Stylists Promote Breast Cancer Prevention Messages to Clients   Manchester researchers announce new methods of beating breast cancer   Cardiac Effects Associated with Breast Cancer Treatment Appear Lower   Blood thinners like aspirin may fight cancer: study   Link Found Between Vegetables and Decreased Risk of Breast Cancer   New evidence of hormone therapy causing breast cancer, Stanford professor says

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]